People: StemCells Inc (STEM.O)

STEM.O on Consolidated Issue listed on NASDAQ Capital Market

27 Mar 2015
Change (% chg)

$0.01 (+1.33%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

McGlynn, Martin 

Mr. Martin M. McGlynn is Chief Executive Officer, Director of the Company. He served as President, Chief Executive Officer, Director of StemCells, Inc. He has held management positions of increasing responsibility in several countries for more than 30 years. Prior to joining our company, Mr. McGlynn was President and Chief Executive Officer of Pharmadigm, Inc., a privately held company in the fields of inflammation and genetic immunization. Prior to this, he was President and General Manager of Abbott Canada Ltd. and President of Anaquest, Inc., a company focused on anesthesia and acute care pharmaceuticals.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
835,836 -- 43,258 2,118,090

Options Compensation

  Quantity Market Value
Exercisable 844,791 1,121,590.00
Unexercisable 330,209 683,635.00
Exercised 146,000 376,680.00
Name Fiscal Year Total

John Schwartz


Ian Massey


Martin McGlynn


Gregory Schiffman


Ann Tsukamoto


Kenneth Stratton

As Of  30 Dec 2013
Search Stocks